Investigating potential for an oral treatment in diabetic retinopathy First patient dosed in Phase 1b/2a clinical trial COPENHAGEN, Denmark, Jan. 25, 2024 /PRNewswire/ — Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.